Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02030067 · ClinicalTrials.gov registry record · Phase 1
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
A Phase 1 study of Solid Tumor and Metastatic Bladder Cancer, sponsored by Processa Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
- 12
- Study locations
NCT02030067: Completed Phase 1 study of Solid Tumor and Metastatic Bladder Cancer, sponsored by Processa Pharmaceuticals.
NCT02030067 is a Phase 1 study of Solid Tumor and Metastatic Bladder Cancer that has completed, run by Processa Pharmaceuticals. The registered enrollment target is 127 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (43% lower). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02030067, a Phase 1 study of Solid Tumor and Metastatic Bladder Cancer, has completed, sponsored by Processa Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1). The purpose of the Phase 2 portion is to estimate anti-tumor activity in subjects with advanced malignancies (relapsed or refractory pancreatic or advanced bladder cancer).
Primary Outcome
Number of subjects participating in Phase 1 that experienced a DLT during the first cycle of treatment (28 days)
Conditions Studied
Interventions
- DRUG RX-3117
Study Locations (12)
Florida
- Rexahn Site - Miami
- Rexahn Site - Miami Lakes
Alabama
- Rexahn Site - Birmingham
Arizona
- Rexahn Site - Tucson
California
- Rexahn Site - Duarte
Illinois
- Rexahn Site - Skokie
Missouri
- Rexahn Site - St Louis
Nevada
- Rexahn Site - Las Vegas
New York
- Rexahn Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2013-12 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
What the finished NCT02030067 record still lists
NCT02030067 is an interventional study that assigns participants to a tested intervention. The registered 127 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (43% lower).
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which RX-3117 is the first listed.
NCT02030067 lists 12 locations in 11 states (Florida, Alabama, Arizona).
Frequently Asked Questions
What is clinical trial NCT02030067 about?
NCT02030067 is a clinical study titled "Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies". The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1). The purpose of the Phase 2 portion is to estimate anti-tumor activity in subjects with advanced malignancies (relapsed or refractory pancreatic or advanced ...
What is the current status of trial NCT02030067?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2013-12. Estimated completion is 2019-12.
What conditions does trial NCT02030067 study?
This clinical trial studies the following conditions: Solid Tumor, Metastatic Bladder Cancer.
What interventions are being tested in trial NCT02030067?
The interventions under investigation include: RX-3117 (DRUG).
Who is sponsoring clinical trial NCT02030067?
This trial is sponsored by Processa Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02030067 being conducted?
This trial has 12 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02030067's enrollment target sits among peer trials
127 69th of 196 higher than 128 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03017820 · 127 participants · Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- NCT03609580 · 127 participants · Phase 1
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
- NCT06285643 · 127 participants · Phase 2
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
- NCT06809400 · 127 participants · Phase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia